Cargando…
Lp(a): When and how to measure it
Lipoprotein(a) has long been regarded as a risk factor for cardiovascular disease; however, its routine use in clinical practice has been hampered by difficulties inherent in the measurement of this complex lipoprotein. The major challenges relate to its size heterogeneity and related issues includi...
Autores principales: | Cegla, Jaimini, France, Michael, Marcovina, Santica M, Neely, R Dermot G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791270/ https://www.ncbi.nlm.nih.gov/pubmed/33040574 http://dx.doi.org/10.1177/0004563220968473 |
Ejemplares similares
-
Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus
por: Kostner, Karam M., et al.
Publicado: (2022) -
International Federation of Clinical Chemistry (IFCC): Scientific Division, Committee on Apolipoproteins; Working Group of Antibody Reagents: Selection and Characterization of Monoclonal Antibodies for Measuring Plasma Levels of Apolipoproteins A-I and B
por: Marcovina, Santica, et al.
Publicado: (1990) -
Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK
por: Iqbal, Zohaib, et al.
Publicado: (2020) -
Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk
por: Behera, S., et al.
Publicado: (2023) -
Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
por: Enkhmaa, Byambaa, et al.
Publicado: (2020)